| answer text |
<p>The Prime Minister has made clear that a key priority through the negotiations
will be to ensure that the UK remains one of the best places in the world for science
and innovation. As part of those negotiations the Government will discuss with the
EU and Member States how best to continue cooperation in the field of clinical trials.</p><p>
</p><p>Stakeholder engagement is a central element of our plan to build a national
consensus around our negotiating position; we are listening and talking to as many
organisations, companies and institutions as possible. We have been working closely
with business through the joint government and industry, UK EU Life Sciences Steering
Group, to help identify the priorities for our future relationship with the EU for
the benefit of patient health, including clinical trials. We have also engaged stakeholders
from other sectors, including the Association of Medical Research Charities, to discuss
cross cutting issues which may impact our future relationship on clinical trials.
I also attend the Minister of State for Business, Energy and Industrial Strategy’s
Stakeholder Working Group on EU Exit, Universities, Research and Innovation.</p><p>
</p>
|
|
